Benzinga

Benzinga

Benzinga

lundi, septembre 07

Aquestive Therapeutics Inc

AQSTNASDAQ
Trade with Public
Trade with Public
$5.34
-0.01-0.19%
À la clôture: Sep 4, 5:00 PM EST
$5.39
0.050.94%
Après les heures: Sep 4, 7:31 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Aquestive Therapeutics Financials

Aquestive Therapeutics (AQST) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aquestive Therapeutics Q2 EPS $(0.18) Misses $(0.12) Estimate, Sales $13.819M Beat $11.418M Estimate

Benzinga Newsdesk

PRO
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $50.584M Est

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $50.584 million estimate.
Benzinga Newsdesk

PRO
Aquestive Therapeutics Affirms FY2026 Sales Guidance of $46.000M-$50.000M vs $48.072M Est

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2026 sales outlook from $46.000 million-$50.000 million to $46.000 million-$50.000 million vs $48.072 million estimate.
Benzinga Newsdesk

PRO
Aquestive Therapeutics Q1 EPS $(0.07) Beats $(0.15) Estimate, Sales $14.446M Beat $10.896M Estimate

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.15) by 53.33 percent. This is a 70.83 percent increase over losses of $(0.24) per share
Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

Aquestive Therapeutics Q4 Earnings Assessment

Benzinga Insights

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved